Peripheral Artery Disease (PAD) is a common circulatory condition in which narrowed arteries reduce blood flow to the legs, causing pain, fatigue, and discomfort when walking. Over time, it can restrict mobility, cause ulcers, and significantly increase the risk of heart attack or stroke. PAD is often underdiagnosed; up to half of people with the condition experience no obvious symptoms, meaning many people are unaware they have it.
In Australia during 2021-22, approximately 54,500 hospitalisations with PAD were recorded.
As of
2023-2025, about 113 to 236 million people (1 in 20 adults globally) lived with PAD worldwide, mainly aged 40+. Because PAD shares many of the same risk factors as heart disease and stroke, people living with the condition face a significantly higher risk of serious cardiovascular events.
This trial is evaluating a once-daily oral tablet that may help improve walking ability and overall well-being in people with PAD, offering a potential new option for those whose symptoms continue to limit their daily lives.
Do you experience leg pain or fatigue when walking? You may be eligible even without a PAD diagnosis; people with two or more cardiovascular risk factors such as a history of heart attack, stroke, diabetes, or long-term smoking can now qualify for screening. Speak to our recruitment team to find out if you qualify.
treatment design
Eligible participants will be randomly assigned to receive either the investigational tablet or a placebo, taken once daily. The trial runs for up to 58 weeks, including a 4-week screening period, 52 weeks of treatment, and a 2-week safety follow-up.
Participants will attend up to 14 scheduled visits at our Meadowbrook clinic, with some check-ins potentially conducted by phone. All procedures will be explained clearly, and
